Trial · NCT07037836
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ventilation Defect Percentage (VDP) on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with ventilation signals \< mean - 2SD, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | Membrane Defect Percentage on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with membrane signals \< mean - 2SD, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | Low Membrane Region Percentage on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with membrane signals between 1SD and 2SD below the mean, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | RBC Transfer Defect Percentage on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with RBC transfer signals \< mean - 2SD, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | Low RBC Transfer Region Percentage on HP129XeMRI | Baseline and 4 weeks post-Tyvaso | Defined as the region with RBC transfer signals between 1SD and 2SD below the mean, measured by HP129XeMRI and expressed as a percentage of total lung volume. |
| Primary | RBC Oscillation Amplitude Normalized for RBC Transfer Defect | Baseline and 4 weeks post-Tyvaso | Measured using HP129XeMRI spectroscopy as a surrogate for pulmonary vascular resistance, normalized to RBC transfer signal intensity. |
| Primary | RBC Chemical Shift on HP129XeMRI Spectroscopy | Baseline and 4 weeks post-Tyvaso | Frequency shift in RBC signal reflecting capillary blood oxygenation, measured using HP129XeMRI spectroscopy. |
| Secondary | Nadir SpO₂ During 6MWT | Baseline and 4 weeks post-Tyvaso treatment | Lowest oxygen saturation (SpO₂) recorded during the 6-minute walk test, measured by pulse oximetry. The test is performed on room air unless SpO₂ drops below 89%, at which point supplemental oxygen is administered to maintain SpO₂ ≥89%. |
| Secondary | Supplemental Oxygen Flow During 6MWT | Baseline and 4 weeks post-Tyvaso treatment | Oxygen flow rate in liters per minute required to maintain SpO₂ ≥89% during the 6-minute walk test if room air is insufficient. |
| Secondary | 6-Minute Walk Distance (6MWD) | Baseline and 4 weeks post-Tyvaso treatment | Total distance walked in meters during the 6-minute walk test, following ATS guidelines. |
| Secondary | Dyspnea Score During 6MWT | Baseline and 4 weeks post-Tyvaso treatment | Subjective rating of dyspnea severity on a 1-10 scale reported by participants at the end of the 6-minute walk test. |
| Secondary | Peak Heart Rate (% Predicted) During 6MWT | Baseline and 4 weeks post-Tyvaso treatment | Highest heart rate achieved during the 6-minute walk test, expressed as a percentage of predicted maximum heart rate. |
| Secondary | Forced Expiratory Volume in 1 Second (FEV1) - Absolute and % Predicted | Baseline and 4 weeks post-Tyvaso treatment | EV1 measured in liters and as a percentage of predicted value, assessed by spirometry. |
| Secondary | Forced Vital Capacity (FVC) - Absolute and % Predicted | Baseline and 4 weeks post-Tyvaso treatment | FVC measured in liters and as a percentage of predicted value, assessed by spirometry |
| Secondary | Total Lung Capacity (TLC) - Absolute and % Predicted | Baseline and 4 weeks post-Tyvaso treatment | TLC measured in liters and as a percentage of predicted value, assessed by lung volume testing. |
| Secondary | Residual Volume (RV) - Absolute and % Predicted | Baseline and 4 weeks post-Tyvaso treatment | RV measured in liters and as a percentage of predicted value, assessed by lung volume testing. |
| Secondary | Diffusing Capacity for Carbon Monoxide (DLCO) - Absolute and % Predicted | Baseline and 4 weeks post-Tyvaso treatment | DLCO measured in mL/min/mmHg and as a percentage of predicted value, assessed by single-breath method. |
| Secondary | Carbon Monoxide Transfer Coefficient (KCO) - Absolute and % Predicted | Baseline and 4 weeks post-Tyvaso treatment | KCO measured in mL CO/min/mmHg/L and as a percentage of predicted value, derived from DLCO and alveolar volume. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07037836/registered